Detalles de la búsqueda
1.
Safety of First-Line Nivolumab Plus Ipilimumab in Patients With Metastatic NSCLC: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817.
J Thorac Oncol
; 18(1): 79-92, 2023 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36049658
2.
Continuous Versus 1-Year Fixed-Duration Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: CheckMate 153.
J Clin Oncol
; 38(33): 3863-3873, 2020 11 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-32910710
3.
Safety, Efficacy, and Patient-Reported Health-Related Quality of Life and Symptom Burden with Nivolumab in Patients with Advanced Non-Small Cell Lung Cancer, Including Patients Aged 70 Years or Older or with Poor Performance Status (CheckMate 153).
J Thorac Oncol
; 14(9): 1628-1639, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31121324
4.
Safety profile of nivolumab administered as 30-min infusion: analysis of data from CheckMate 153.
Cancer Chemother Pharmacol
; 81(4): 679-686, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29442139
Resultados
1 -
4
de 4
1
Próxima >
>>